Condition: Low Grade Glioma · Sponsor: University Hospital Heidelberg
Low-grade glioma (LGG) represent typically slowly growing primary brain tumors with world health organization (WHO) grade I or II who affect young adults around their fourth decade. Radiological feature on MRI is a predominantly T2 hyperintense signal, LGG show typically no contrast uptake. Radiotherapy plays an important role in the treatment of LGG. However, not least because of the good prognosis with long term survivorship the timing of radiotherapy has been discussed controversially. In order to avoid long term sequelae such as neurocognitive impairment, malignant transformation or secondary neoplasms initiation was often postponed as long as possible
This description comes directly from the study's public registry record.
Semi Harrabi, MD · +496221 56 · semi.harrabi@med.uni-heidelberg.de
Adriane Lentz-Hommertgen, Phd · +496221 56 · adriane.lentz-hommertgen@med.uni-heidelberg.de
Always discuss trial participation with your own doctor first.
| Department of Radiotherapy, University of Heidelberg | Heidelberg, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05964569